v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:        
Total revenue $ 189,948 $ 157,370 $ 363,881 $ 300,907
Cost of revenue:        
Total cost of revenue 76,750 60,781 149,522 116,090
Gross profit 113,198 96,589 214,359 184,817
Operating expenses:        
Research, development and clinical trials 31,632 15,934 56,511 33,094
Selling, general and administrative 57,830 44,088 120,815 87,713
Total operating expenses 89,462 60,022 177,326 120,807
Income from operations 23,736 36,567 37,033 64,010
Other income (expense):        
Interest expense (7,225) (3,476) (14,395) (6,937)
Interest income and other income (expense), net 2,894 3,091 5,252 5,785
Total other expense, net (4,331) (385) (9,143) (1,152)
Income before income taxes 19,405 36,182 27,890 62,858
Provision for income taxes (4,723) (1,275) (5,893) (2,269)
Net income $ 14,682 $ 34,907 $ 21,997 $ 60,589
Net income per share, basic $ 0.42 $ 1.03 $ 0.64 $ 1.79
Net income per share, diluted $ 0.41 $ 0.92 $ 0.61 $ 1.62
Weighted average common shares outstanding, basic 34,579,980 33,912,669 34,482,634 33,817,664
Weighted average common shares outstanding, diluted 40,709,227 40,558,953 36,003,677 40,238,501
Net product revenue [Member]        
Revenue:        
Total revenue $ 111,158 $ 96,100 $ 219,130 $ 184,334
Cost of revenue:        
Total cost of revenue 25,566 19,421 49,874 35,733
Service Revenue [Member]        
Revenue:        
Total revenue 78,790 61,270 144,751 116,573
Cost of revenue:        
Total cost of revenue $ 51,184 $ 41,360 $ 99,648 $ 80,357